Advanta Dx SARS-CoV-2 RT-PCR Assay and Genomics Research Assays for CoVID-19 | Ganesh Babu, PhD
8 July 2020
Speaker: Ganesh Babu, PhD, Field Applications Scientist, Fluidigm
In a short period of time, a novel coronavirus (SARS-CoV-2) has impacted our lives, society and health care infrastructure. Fluidigm has developed a high-throughput, extraction-free diagnostic test for the detection of SARS-CoV-2 in saliva specimens and filed for FDA Emergency Use Authorization (EUA).
The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Fluidigm's proprietary microfluidics technology and Juno™ and Biomark™ HD systems, enables high throughput and scalable testing of saliva samples from patients suspected of COVID-19 (coronavirus) infection. Featuring extraction-free sample processing, a modular workflow and large batch-sample size, the Advanta Dx SARS-CoV-2 RT-PCR Assay could enhance laboratory testing capacity while providing reliable results to support clinical decision making. Learn about this innovative workflow and find out how to implement our microfluidics into your lab.